FDA-approved intranasal esketamine for treatment-resistant depression, administered under clinical supervision. Spravato provides a novel glutamatergic mechanism of action distinct from traditional antidepressants and is used within a structured, monitored psychiatric protocol to support symptom reduction and functional restoration.

Pharmacogenetic testing that evaluates genetic variation in medication metabolism and response. This allows for precision-guided psychiatric prescribing, reducing trial-and-error and improving alignment between medication choice, neurobiology, and clinical response.

Clinically guided cannabis therapy for psychiatric symptom management, including anxiety disorders, PTSD-related symptoms, sleep dysregulation, and mood instability. Treatment is individualized based on symptom profile, neurobiological response, and functional goals within a structured psychiatric framework.

A rapid-acting, NMDA receptor–modulating intervention used in treatment-resistant depression and complex mood disorders. Ketamine targets glutamatergic dysfunction and neuroplasticity pathways, often producing rapid symptom reduction when standard treatments have been insufficient. Delivered as part of a structured psychiatric treatment plan with ongoing monitoring and integration.